ResearchMoz added Latest Research Report titled ” Research and Development Prospect of China Dialysis Market, 2014-2018 ” to it’s Large Report database.
Based on the 2013 version, this update Report provides detailed analysis on Chinese government policies about dialysis industry and the relevant effect in recent three years, and conducts in-depth research about dialysis industry segmentations. Moreover, it analyzes Chinese private-owned hemodialysis services. In the aspect of enterprises, this update Report not only updates the latest information about the key enterprises listed in 2013 version, but also adds the information about some enterprises who intend to enter into this industry. This update Report reflects an overall development situation of Chinas dialysis industry and provides references for investors and entrepreneurs.
In China, hemodialysis treatment has gained a wide popularity. By the end of 2013, the number of dialysis centers has amounted to 3637, contributing a make scale of CNY 14.4 billion, in which, hemodialysis was CNY 11.5 billion, and peritoneal dialysis was CNY 2.9 billion.
Download free Sample PDF report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=226529
Foreign enterprises, such as, Germany Fresenius, Japan Nikkiso and Asahi Kasei, have dominated Chinas dialysis market. Chinese enterprises mainly are engaged in the production of dialysis tubing or dialysate and other low technology content products. And few Chinese enterprises are specialized in manufacturing dialysis machines and dialyzers or other high end products. Now the situation improved a little, Chinese enterprise Weigao has led Chinas hemodialysis machines and dialyzers manufacture, and Chinese enterprise Huaren Pharma has led Chinas peritoneal dialysis industry.
By the end of May 2014, rural residence critical illness insurance program has already covered over 50% counties (cities and districts) in whole China. And in Shandong, Tianjin, Jilin, Gansu, and Qinghai, and some other cities and provinces, the critical illness insurance program is in full swing, and the provincial government has implemented the overall planning in each administrative region. Huidian Research believes that along with the gradual implementation of critical illness program in China, more and more ESRD (End Stage Renal Disease) patients will enjoy the insurance guarantee. Therefore, Chinas dialysis industry is entering into golden development stage.
Read All Healthcare Market Research Reports @ http://www.researchmoz.us/healthcare-market-reports-56.html
Table of Content
1. Overview of Dialysis Market
1.3 Historical Development
2. Global Dialysis Market
2.1 Morbidity of Chronic Renal Failure
2.2 Dialysis Product Market
2.2.1 General Situation of Global Dialysis Product Market
2.2.2 Products Made in Europe, America, and Japan Take up the Lions Share in Global Market
2.2.3 Fresenius Becomes the Giant in Manufacturing Hemodialysis Products
2.2.4 Baxter Becomes the Giant in Manufacturing Peritoneal Dialysis Products
2.3 Dialysis Treatment Market
2.3.1 Overview of Global Market
2.3.2 Market Situations in America, Japan, and China
3. Current Status of Chinas Dialysis Market
3.1 Development Status
3.2 Competition Landscape of Product Segmentations
3.3 Policy Environment
3.3.1 Gradual Implementation of Critical Illness Insurance Program
3.3.2 Dialysis treatment has the priority to enjoy more benefits in the current short term, while the situation in the long run is determined by Medical Insurance Policy
ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Albany NY, United States – 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://healthcare-research-report.blogspot.in/